CAR-T cell therapy for targeting the CD19 antigen has been established for relapsed or refractory disease in young people with CD19-positive acute B-cell leukemia (B-acute lymphoblastic leukemia, B-ALL) and diffuse large B-cell lymphoma (DLBCL) [120]. The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.